- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03546322
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers
Přehled studie
Detailní popis
The investigators aim to implement and evaluate a health information technology (HIT) registry at an urban, public delivery system. The investigators will not assign specific interventions to the study participants, but rather observationally assess the effect of the HIT registry, designed to support routine medical care, on participants.
The investigators will use systems engineering methodologies to design, develop, and implement the platform. The platform will be implemented in the Otolaryngology - Head and Neck Surgery clinic that cares for patients with head and neck cancers. The study will assess patient outcomes and evaluate the time it takes for patients to progress through key treatment and post-treatment milestones before and after the HIT tool is implemented. The investigators will use models controlling for secular trend to estimate the effect of the tool on improving timely and successful completion of guideline-based care processes.
The HIT platform seeks to improve the monitoring and alerting functionality of existing systems. Specifically, it replaces paper-based systems previously used by the clinic to monitor its head and neck cancer patients. It will be implemented clinic-wide for all patients being treated for head and neck cancers. The investigators are not assigning a specific intervention to patients, but rather supporting the clinic and health system in the development of a population management platform that improves routine care processes. The platform is approved for clinical use and research by the San Francisco Health Network and the University of California, San Francisco.
The HIT platform users are clinicians who are responsible for monitoring patients with head and neck cancer and agree to partner with the investigators to improve monitoring processes. The clinicians involved may be asked to voluntarily participate in surveys, interviews, focus groups, and program evaluations. Patient medical records will be reviewed, but patients monitored on the registry will not be contacted by researchers.
Procedures are in place to monitor the registry. First, quality assurance is performed by the research team, information technology analysts, and software engineers. This includes checking that data in the platform matches source data, such as data entered in the electronic health record. In addition, the platform users are audited on a weekly basis. A data dictionary defining variables used in the platform exists and is updated as needed. Patients will be added to the registry by a clinician if they are diagnosed with head and neck cancer. The research team will support the clinicians in data analysis, although this will be performed with population-level, de-identified data. However, if unmediated adverse events are identified by the research team, the research team will alert the clinicians immediately. The HIT platform is designed to supplement, but not replace, the existing electronic health record. Data on the registry will be validated with source data and users will still engage with the source data and electronic health record as appropriate clinically and operationally.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
California
-
San Francisco, California, Spojené státy, 94110
- Zuckerberg San Francisco General Hospital and Trauma Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Patients with head and neck surgery monitored by the Otolaryngology - Head and Neck Surgery Clinic
Exclusion Criteria:
- N/A
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Registry
Head and neck cancer patients monitored on registry
|
Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group.
The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients.
All head and neck cancer patients monitored by the clinic will be included.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Workup and Treatment Planning - Primary Outcome
Časové okno: From date of diagnosis to first date of treatment, assessed up to 5 years
|
Time from diagnosis to initiation of treatment
|
From date of diagnosis to first date of treatment, assessed up to 5 years
|
|
Treatment - Primary Outcome
Časové okno: 5 years
|
Proportion of patients that complete tumor board treatment recommendations
|
5 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Workup and Treatment Planning - Secondary Outcome #1
Časové okno: From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
Time from diagnosis to presentation at tumor board
|
From date of diagnosis to presentation at tumor board, assessed up to 5 years
|
|
Workup and Treatment Planning - Secondary Outcome #2
Časové okno: From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
Time from diagnosis to dental evaluation
|
From date of diagnosis to date of dental evaluation for patients undergoing radiation treatment, assessed up to 5 years
|
|
Workup and Treatment Planning - Secondary Outcome #3
Časové okno: From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
Time from diagnosis to first visit in oncology clinics
|
From date of diagnosis to date of first visit with oncology clinic, assessed up to 5 years
|
|
Treatment - Secondary Outcome
Časové okno: 6 weeks
|
Proportion of patients who complete post-treatment radiation
|
6 weeks
|
|
Loss to follow-up
Časové okno: 5 years
|
Proportion of patients who are lost to follow-up
|
5 years
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Urmimala Sarkar, MD, MPH, University of California, San Francisco
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- P30HS023558-1
- P30HS023558 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .